M. Vincent

2.8k total citations · 1 hit paper
28 papers, 2.2k citations indexed

About

M. Vincent is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, M. Vincent has authored 28 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 5 papers in Hematology and 5 papers in Genetics. Recurrent topics in M. Vincent's work include Neutropenia and Cancer Infections (11 papers), Blood disorders and treatments (5 papers) and Acute Myeloid Leukemia Research (4 papers). M. Vincent is often cited by papers focused on Neutropenia and Cancer Infections (11 papers), Blood disorders and treatments (5 papers) and Acute Myeloid Leukemia Research (4 papers). M. Vincent collaborates with scholars based in United States, Canada and Australia. M. Vincent's co-authors include Howard Ozer, David H. Johnson, Mark G. Kris, Gary H. Lyman, Ronald G. Stoller, Morgan E. Stewart, Vincent J. Picozzi, William J. Gradishar, Imad A. Tabbara and Roy E. Smith and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

M. Vincent

28 papers receiving 2.1k citations

Hit Papers

Reduction by Granulocyte Colony-Stimulating Factor of Fev... 1991 2026 2002 2014 1991 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
    1991 1.1k citations Jeffrey Crawford, Howard Ozer et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Vincent United States 14 1.5k 793 652 352 301 28 2.2k
WE Fibbe Netherlands 24 498 0.3× 181 0.2× 823 1.3× 88 0.3× 759 2.5× 36 1.9k
BM Camitta United States 22 858 0.6× 265 0.3× 2.4k 3.6× 161 0.5× 618 2.1× 33 2.9k
Joel A. Brochstein United States 19 407 0.3× 393 0.5× 841 1.3× 91 0.3× 415 1.4× 40 1.5k
Erik Forestier Sweden 36 745 0.5× 299 0.4× 2.3k 3.5× 104 0.3× 178 0.6× 109 4.2k
J M Chessells United Kingdom 29 315 0.2× 205 0.3× 1.3k 2.0× 101 0.3× 163 0.5× 62 2.5k
Joel M. Rappeport United States 26 293 0.2× 261 0.3× 960 1.5× 65 0.2× 913 3.0× 49 2.1k
Paolo de Fabritiis Italy 32 708 0.5× 158 0.2× 1.8k 2.8× 94 0.3× 381 1.3× 199 3.2k
K. Hählen Netherlands 39 612 0.4× 182 0.2× 2.1k 3.3× 79 0.2× 425 1.4× 84 4.1k
Barbara Degar United States 20 514 0.3× 146 0.2× 1.1k 1.7× 57 0.2× 696 2.3× 48 2.5k
Johannes Blom Sweden 25 1.3k 0.8× 103 0.1× 263 0.4× 57 0.2× 97 0.3× 87 2.4k

Countries citing papers authored by M. Vincent

Since Specialization
Citations

This map shows the geographic impact of M. Vincent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Vincent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Vincent more than expected).

Fields of papers citing papers by M. Vincent

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Vincent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Vincent. The network helps show where M. Vincent may publish in the future.

Co-authorship network of co-authors of M. Vincent

This figure shows the co-authorship network connecting the top 25 collaborators of M. Vincent. A scholar is included among the top collaborators of M. Vincent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Vincent. M. Vincent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goodman, Chelain R., et al.. (2019). Gemcitabine-Induced Pseudocellulitis: A Case Report and Review of the Literature. Current Oncology. 26(5). 703–706. 4 indexed citations
2.
Ko, Y.J., Mahmoud Abdelsalam, Petr Kavan, et al.. (2019). What Is a Clinically Meaningful Survival Benefit in Refractory Metastatic Colorectal Cancer?. Current Oncology. 26(2). 255–259. 5 indexed citations
3.
Rosenberg, Jonathan E., Elisabeth I. Heath, Raymond P. Perez, et al.. (2016). Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC). Annals of Oncology. 27. vi273–vi273. 9 indexed citations
4.
Petrylak, Daniel P., Elisabeth I. Heath, Guru Sonpavde, et al.. (2016). Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC). Annals of Oncology. 27. vi269–vi269. 27 indexed citations
5.
Rosenberg, Jonathan E., Elisabeth I. Heath, Peter J. Van Veldhuizen, et al.. (2016). Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology. 34(15_suppl). 4533–4533. 6 indexed citations
6.
Petrylak, Daniel P., Elisabeth I. Heath, Guru Sonpavde, et al.. (2016). Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology. 34(15_suppl). 4532–4532. 9 indexed citations
7.
Wolpin, Brian M., Eileen M. O’Reilly, Yoo-Joung Ko, et al.. (2013). Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Annals of Oncology. 24(7). 1792–1801. 29 indexed citations
8.
Morris, Michael J., Mario A. Eisenberger, Роберто Пили, et al.. (2012). A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of Oncology. 23(10). 2714–2719. 29 indexed citations
9.
Carducci, Michael A., Michael J. Morris, Mario Eisenberger, et al.. (2007). Phase I dose-escalation study of AGS-PSCA, an anti-PSCA human antibody, in castration-resistant prostate cancer. Molecular Cancer Therapeutics. 6. 2 indexed citations
10.
Dranitsaris, George, M. Clemons, Santosh K. Verma, & M. Vincent. (2007). P102 Development of a risk prediction model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy. The Breast. 16. S41–S42. 1 indexed citations
11.
Lapointe, Réjean, William P. Steward, Robert E. Hawkins, et al.. (2005). Phase II study of troxacitabine in chemotherapy-naïve patients with advanced cancer of the pancreas. Annals of Oncology. 16(2). 289–293. 18 indexed citations
12.
Foote, MaryAnn, D. Garth Perkins, M. Vincent, & George Morstyn. (1994). The clinical utility of granulocyte colony‐stimulating factor: Early achievements and future promise. Stem Cells. 12(S1). 213–228. 11 indexed citations
13.
Weston, Brent W., Richard A. Axtell, Robert F. Todd, et al.. (1991). Clinical and biologic effects of granulocyte colony stimulating factor in the treatment of myelokathexis. The Journal of Pediatrics. 118(2). 229–234. 36 indexed citations
14.
Crawford, Jeffrey, Howard Ozer, Ronald G. Stoller, et al.. (1991). Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. New England Journal of Medicine. 325(3). 164–170. 1109 indexed citations breakdown →
15.
Greenberg, P, et al.. (1990). Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Stem Cells. 8(S1). 293–302. 17 indexed citations
16.
Morstyn, George, Lynda J. Campbell, Graham J. Lieschke, et al.. (1989). Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.. Journal of Clinical Oncology. 7(10). 1554–1562. 136 indexed citations
17.
Bonilla, Mary Ann, AP Gillio, Nancy A. Kernan, et al.. (1989). Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on Neutropenia in Patients with Congenital Agranulocytosis. New England Journal of Medicine. 320(24). 1574–1580. 381 indexed citations
18.
Vincent, M.. (1979). Physicians after 65.. PubMed. 120(8). 998, 1001–998, 1001. 2 indexed citations
19.
Vincent, M., et al.. (1969). Physicians as patients: private psychiatric hospital experience.. PubMed. 100(9). 403–12. 26 indexed citations
20.
Vincent, M.. (1969). Doctor and Mrs. — Their Mental Health. Canadian Psychiatric Association Journal. 14(5). 509–515. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by WE Fibbe Breakdown of academic impact, for papers by BM Camitta Breakdown of academic impact, for papers by Joel A. Brochstein Breakdown of academic impact, for papers by Erik Forestier Breakdown of academic impact, for papers by J M Chessells Breakdown of academic impact, for papers by Joel M. Rappeport Breakdown of academic impact, for papers by Paolo de Fabritiis Breakdown of academic impact, for papers by K. Hählen Breakdown of academic impact, for papers by Barbara Degar Breakdown of academic impact, for papers by Johannes Blom
Rankless by CCL
2026